TG Therapeutics Stock: Riding a Wave of Commercial Success

TG Therapeutics is demonstrating extraordinary momentum, largely driven by the remarkable performance of its flagship therapy. While numerous pharmaceutical companies face growth challenges, this biotechnology specialist is delivering impressive results and providing shareholders with dual benefits. The critical question for investors is whether this represents a sustainable shift in the company’s trajectory.

Robust Financial Performance and Upward Revision

The company’s primary revenue driver, BRIUMVI, is rapidly establishing itself as a commercial success story. TG Therapeutics reported total second-quarter 2025 revenue of $141.1 million, with U.S. sales of BRIUMVI contributing $138.8 million to this figure. This represents a substantial 91 percent year-over-year increase, highlighting the therapy’s accelerating market adoption for multiple sclerosis treatment.

In response to this powerful sales trajectory, management has significantly raised its full-year 2025 guidance. Instead of previous projections, TG Therapeutics now anticipates approximately $570 to $575 million in U.S. BRIUMVI revenue alone—a strong indicator of continued robust demand.

Shareholder Value Enhancement Through Capital Allocation

Management’s growing confidence in the company’s prospects is directly reflected in its capital allocation strategy. On September 3, 2025, the firm completed a $100 million stock repurchase program and immediately announced a new program of identical magnitude. This aggressive buyback approach strongly suggests that leadership considers the current valuation significantly undervalued.

Should investors sell immediately? Or is it worth buying TG Therapeutics?

Solid financial fundamentals support this optimistic stance. With second-quarter net income reaching $28.2 million—quadruple the amount from the same period last year—and a strong liquidity position of $278.9 million, TG Therapeutics maintains ample flexibility for additional strategic investments in growth initiatives.

Global Expansion and Development Pipeline

The company’s success extends beyond domestic markets. Regulatory approvals for BRIUMVI in the European Union, United Kingdom, Switzerland, and Australia present substantial additional growth opportunities. Concurrently, TG Therapeutics is advancing development of a subcutaneous formulation and optimized dosing regimens that could further enhance patient convenience and treatment accessibility.

Sustainability of Momentum

Chief Executive Officer Michael S. Weiss has been actively presenting the company’s progress at recent investor conferences. Market recognition is evident in the stock’s appreciation of over 40 percent during the past twelve months. The pivotal consideration for investors remains whether current momentum can sufficiently narrow the gap to the 52-week high, which stands at over 31 percent above recent trading levels.